Search clinical trials for: BAT1406

Total 67 results

Bio-Thera Solutions

Unknown

A Phase I Clinical Trial of BAT1306 and BAT8001 Injection in Patients With Solid Tumor

Solid Tumor

China
Bio-Thera Solutions

Recruiting

A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders

Optic Neuromyelitis Spectrum Disease

China
Bio-Thera Solutions

Not yet recruiting

A Comparative Pharmacokinetic Study to Evaluate Different Manufacturing Batches of BAT1706 Injection

Healthy Men

China
Bio-Thera Solutions

Completed

Clinical Study of the Safety and Efficacy of BAT5906 Injection

Diabetic Macular Edema

China
Bio-Thera Solutions

Recruiting

Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT1308 in Advanced Solid Tumors

Advanced Solid Tumor

China
Bio-Thera Solutions

Active, not recruiting

A Randomized, Double-blind, Single-dose, Two-arm Parallel Study to Compare the Pharmacokinetics and Safety of BAT1806 Prefilled Subcutaneous Injection With RoActemra® in Healthy Chinese Male Subjects

Healthy Men

China
Biogen

Recruiting

A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants

Healthy Volunteer

United States
Bio-Thera Solutions

Completed

Clinical Study on the Efficacy and Safety of BAT5906 Injection

Wet Age-related Macular Degeneration

China
Bio-Thera Solutions
Peking University Cancer Hospital & Institute

Recruiting

Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT4706 in Advanced Solid Tumors

Melanoma | Advanced Solid Tumor

China
Bio-Thera Solutions

Recruiting

A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders

Neuromyelitis Optica Spectrum Disorders

China
Bio-Thera Solutions

Not yet recruiting

An Evaluation of BAT 8010 for Injection in Combination With BAT 1006 in Locally Advanced or Metastatic Entities Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of the Tumor in Patients Multicenter, Open Phase Ib/IIa Clinical Study

Advanced Solid Tumors
Bio-Thera Solutions

Completed

A Phase I Clinical Trial of BAT5906 Injection in Patients With Wet Age-related Macular Degeneration

Age-related Macular Degeneration

China
Bio-Thera Solutions

Completed

Comparative Study to Evaluate the Pharmacokinetics of BAT1806 vs Actemra® in Healthy Subjects

Rheumatoid Arthritis

China
Shandong Boan Biotechnology Co., Ltd

Recruiting

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1106 in Advanced Solid Tumors

Solid Tumors

China
Bio-Thera Solutions

Completed

Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects

Severe Asthma

China
Biokine Therapeutics Ltd

Completed

Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients

Multiple Myeloma

Israel
Bio-Thera Solutions

Completed

A Phase III Study Evaluate the Efficacy and Safety of BAT1406 and Humira

Ankylosing Spondylitis
Bio-Thera Solutions

Completed

Comparative Study of BAT1806 to RoActemra® in Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate

Rheumatoid Arthritis

China
Bio-Thera Solutions

Not yet recruiting

A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors

Advanced Solid Tumors
Bio-Thera Solutions

Completed

Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects

Psoriatic Arthritis

China
Bio-Thera Solutions

Recruiting

Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Patients

Advanced Solid Tumor

China
Bio-Thera Solutions

Completed

Comparative Study to Evaluate the Pharmacokinetics of BAT2206 vs Stelara® in Healthy Subjects

Psoriasis

China
Bio-Thera Solutions

Active, not recruiting

Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006

Advanced Solid Tumor

China
BeiGene

Completed

A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC

Advanced Hepatocellular Carcinoma

China, Taiwan
Bio-Thera Solutions

Completed

Comparative Study of BAT2206 With Stelara® in Patients With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

China
Bio-Thera Solutions

Completed

Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy Subjects

Psoriasis

China
Bio-Thera Solutions

Completed

Study of Bevacizumab(BAT1706) and Comparators in Healthy Subjects

NSCLC

New Zealand
Bio-Thera Solutions

Active, not recruiting

Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients

Plaque Psoriasis

China
Bio-Thera Solutions

Recruiting

Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration

Neovascular (Wet) Age-related Macular Degeneration

China
Bio-Thera Solutions

Completed

Comparative Study of BAT2506 With Simponi® in Participants With Active Psoriatic Arthritis

Psoriatic Arthritis

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Recurrent Pancreatic Adenocarcinoma

United States
Bio-Thera Solutions

Recruiting

Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection

Advanced Solid Tumors

China
Bio-Thera Solutions

Terminated

Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients

Advanced Solid Tumor

Australia
Bio-Thera Solutions

Completed

A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer

Non-squamous Non-small Cell Lung Cancer

China, Mexico, South Africa, Turkey, Ukraine
Bio-Thera Solutions

Terminated

Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumour Patients

Advanced Solid Tumour

Australia
Bio-Thera Solutions
The First Hospital of Jilin University

Completed

A Study on Pharmacokinetics and Safety of BAT2506 Injection Versus Simponi®

Psoriatic Arthritis

China
National Cancer Institute (NCI)

Active, not recruiting

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Recurrent... and other conditions

United States
Bio-Thera Solutions
Wuhan Union Hospital, China

Active, not recruiting

Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects

Healthy Male Subjects

China
Bio-Thera Solutions

Recruiting

BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer

Endometrial Cancer

China
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma

United States
Bio-Thera Solutions

Not yet recruiting

A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC

Carcinoma, Non-Small-Cell Lung
National Cancer Institute (NCI)

Recruiting

Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

Metastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Ovarian High Grade Serous Adenocarcinoma | Platinum-Resistant... and other conditions

United States, Canada
Bio-Thera Solutions

Not yet recruiting

BAT1308 Combined With Platinum-Based Chemotherapy± Bevacizumab For PDL1-Positive (CPS ≥1) Cervical Cancer

Cervical Cancer

China
National Cancer Institute (NCI)

Active, not recruiting

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

Recurrent Glioblastoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Carcinoid Tumor | Neuroendocrine Neoplasm | Colorectal Neuroendocrine Tumor G1 | Gastric Neuroendocrine Tumor G1 | Neuroendocrine Tumor G2

United States
National Cancer Institute (NCI)

Active, not recruiting

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Brain

United States
National Cancer Institute (NCI)

Completed

Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma

Brain Stem Glioma | Childhood Spinal Cord Neoplasm | Childhood Cerebral Anaplastic Astrocytoma | Cerebral Astrocytoma | Childhood Cerebellar Anaplastic Astrocytoma

United States, Canada
BeiGene

Enrolling by invitation

Study of Tislelizumab and/or Pamiparib Containing Treatments in Participants With Advanced Malignancies

Advanced Malignancies

China, Taiwan, Korea, Republic of, Turkey
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous Adenocarcinoma and other conditions

United States, Korea, Republic of, Canada

3

Subscribe